[td_text_with_title custom_title=”Company description”]Santhera is focusing on the development and commercialization of innovative treatments of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy. Strategically, Santhera focuses on Raxone®/Catena® (INN: idebenone) in mutliple indications.[/td_text_with_title]


    Idebenone is Santhera's lead compound and is being developed in a number of orphan mitochondrial and neuromuscular indications, areas of high medical need with no current therapies. Idebenone, a synthetic short-chain benzoquinone and a cofactor for the enzyme NAD(P)H: quinone oxidoreductase (NQO1) is capable of transferring electrons directly onto complex III of the mitochondrial electron [...]
    [td_text_with_title custom_title=”Latest post”]

    Posts not found